Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Assay sensitivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    157 result(s) found for: Assay sensitivity. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2012-005395-34 Sponsor Protocol Number: CTC-cDDP Start Date*: 2013-04-25
    Sponsor Name:Erasmus MC
    Full Title: Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000925-38 Sponsor Protocol Number: UCL13/0076 Start Date*: 2017-01-04
    Sponsor Name:University College London (UCL)
    Full Title: GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding Factor VIII-V3
    Medical condition: Severe Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005838-22 Sponsor Protocol Number: CLIO Start Date*: 2016-07-22
    Sponsor Name:UZLeuven
    Full Title: Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in Ovarian Cancer (CLIO). Establishing the value of a ctDNA-based HRD assay for predicting olaparib response in women with relapsed ovar...
    Medical condition: platinum-sensitive and platinum-resistant relapsed ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002853-21 Sponsor Protocol Number: RGHT000405 Start Date*: 2007-09-03
    Sponsor Name:Belfast Health & Social Care Trust [...]
    1. Belfast Health & Social Care Trust
    2. South Eastern Health & Social Care Trust
    Full Title: A randomized controlled trial of tea tree oil (5%) body wash versus standard body wash to prevent colonization with methicillin-resistant Staphylococcus aureus (MRSA) in critically ill adults
    Medical condition: Colonization with methicillin-resistant Staphylococcus aureus (MRSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001880-68 Sponsor Protocol Number: 1001-PR-PRI-133 Start Date*: 2005-09-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: Standardization of Latex allergenic extract. Determination of biological activity in HEP units
    Medical condition: The objective of the study is to know the biologic activity of the Latex reference extract (IHRP) in HEP units. The HEP value will be the reference of every other diagnostic or treatment preparations.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001440-22 Sponsor Protocol Number: LIVONCO2012/001 Start Date*: 2013-06-26
    Sponsor Name:
    Full Title: A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)
    Medical condition: Histologically/cytologically confirmed diagnosis of metastatic NSCLC. Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000744-10 Sponsor Protocol Number: P.64Cu.003.01 Start Date*: 2019-06-28
    Sponsor Name:A.C.O.M. -ADVANCED CENTER ONCOLOGY MACERATA -S.R.L.
    Full Title: Higher diagnostic accuracy of 64Cu PET/CT compared to standard 18F-choline PET/CT in the detection rate of metastasis from prostate cancer. Phase III multicenter, sponsored, interventional "open-la...
    Medical condition: Prostate cancer at risk of developing metastatic lesions
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015904-24 Sponsor Protocol Number: UKB-2009-MED-I-JKR-01 Start Date*: 2010-10-20
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection i...
    Medical condition: HIV disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002092-42 Sponsor Protocol Number: KF6010/01 Start Date*: 2011-11-04
    Sponsor Name:Grünenthal GmbH
    Full Title: Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain.
    Medical condition: mononeuropathic pain due to post-herpetic neuralgia, post-operative neuropathic pain, or traumatic nerve injury
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003733-15 Sponsor Protocol Number: B-003 Start Date*: 2013-11-13
    Sponsor Name:VU University medical center
    Full Title: The Dutch CSF and PET Biomarker Concordance of Alzheimer’s Disease pathology study
    Medical condition: Patients visiting the VUmc Alzheimer Center with objective cognitive complaints or diagnosed with Alzheimer's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016827-72 Sponsor Protocol Number: GAL-Moa-003 Start Date*: 2010-01-12
    Sponsor Name:Galenica AB
    Full Title: A multicentre, randomized, double-blind, safety and efficacy non-inferiority, intra-individual study, comparing Mometasone furoate Galenica 0.1% cream with Elocon 0.1% cream and placebo in patients...
    Medical condition: Mild to moderate plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018709-12 Sponsor Protocol Number: OSCAR Start Date*: 2010-09-23
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Optimizing Susceptibility to CCR5 Antagonist Response
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008922 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005439-41 Sponsor Protocol Number: PLRG-10/ML29157 Start Date*: 2017-08-13
    Sponsor Name:Polish Lymphoma Research Group (PLRG)
    Full Title: EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE C...
    Medical condition: Molecular relapse after the first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma (MCL) patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000996-38 Sponsor Protocol Number: GMMG-HD8/DSMM-XIX Start Date*: 2023-02-23
    Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg
    Full Title: A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patient...
    Medical condition: Newly diagnosed symptomatic multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002361-22 Sponsor Protocol Number: D5336C00001 Start Date*: 2017-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatm...
    Medical condition: Triple negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Completed) IE (Completed) NL (Completed) PT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003573-34 Sponsor Protocol Number: 270-302 Start Date*: 2018-02-23
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemoph...
    Medical condition: Haemophilia A
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005307-83 Sponsor Protocol Number: CL04041023 Start Date*: 2017-03-03
    Sponsor Name:R-Pharm
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheum...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) DE (Completed) LT (Completed) HU (Completed) PL (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-004139-62 Sponsor Protocol Number: CRAD001JES13 Start Date*: 2014-01-02
    Sponsor Name:Novartis Farmacéutica S. A.
    Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f...
    Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024537-23 Sponsor Protocol Number: AI424-451 Start Date*: 2011-06-22
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimize...
    Medical condition: HIV in paediatric population
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10020172 HIV infection NOS LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002286-30 Sponsor Protocol Number: A8641020 Start Date*: 2014-12-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Medical condition: ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) BE (Prematurely Ended) ES (Completed) DE (Completed) HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 13:40:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA